Navigation Links
Novel nanotherapeutic delivers clot-busting drugs directly to obstructed blood vessels
Date:7/5/2012

Researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University have developed a novel biomimetic strategy that delivers life-saving nanotherapeutics directly to obstructed blood vessels, dissolving blood clots before they cause serious damage or even death. This new approach enables thrombus dissolution while using only a fraction of the drug dose normally required, thereby minimizing bleeding side effects that currently limit widespread use of clot-busting drugs.

The research findings, which were published online today in the journal Science, have significant implications for treating major causes of death, such as heart attack, stroke, and pulmonary embolism, that are caused by acute vascular blockage by blood thrombi.

The inspiration for the targeted vascular nanotherapeutic approach came from the way in which normal blood platelets rapidly adhere to the lining of narrowed vessels, contributing to the development of atherosclerotic plaques. When vessels narrow, high shear stresses provide a physical cue for circulating platelets to stick to the vessel wall selectively in these regions. The vascular nanotherapeutic is similarly about the size of a platelet, but it is an aggregate of biodegradable nanoparticles that have been coated with the clot-busting drug, tissue plasminogen activator (tPA). Much like when a wet ball of sand breaks up into individual grains when it is sheared between two hands, the aggregates selectively dissociate and release tPA-coated nanoparticles that bind to clots and degrade them when they sense high shear stress in regions of vascular narrowing, such as caused by blood clot formation.

Disruption of normal blood flow to the heart, lung, and brain due to thrombosis is one of the leading causes of death and long-term adult disability in the developing world. Today, patients with pulmonary embolism, strokes, heart attacks, and other types of acute thrombosis leading to
'/>"/>

Contact: Twig Mowatt
twig.mowatt@wyss.harvard.edu
Wyss Institute for Biologically Inspired Engineering at Harvard
Source:Eurekalert  

Page: 1 2 3

Related biology technology :

1. Novel clay-based coating may point the way to new generation of green flame retardants
2. Soligenix Announces Collaboration with Infectious Disease Research Institute to Develop Thermostabilized Biodefense Vaccines Utilizing Novel Adjuvants
3. BioMotiv Launches Novel Drug Development Operation, Names Leadership Team
4. State-of-the-Art Novelda NVA6000 Impulse Radar Transceiver Finds Widespread Appeal and Applications
5. Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications
6. Eutropics Pharmaceuticals Receives U.S. Patent for Novel Diagnostic Method
7. Novel radiation surveillance technology could help thwart nuclear terrorism
8. X-BODY BioSciences to Present Novel Methods of Selecting for Antibodies Against Targets on Live Cells at CHIs Protein Engineering Summit
9. Novel compound halts tumor spread, improves brain cancer treatment in animal studies
10. Islet Sciences Announces DiaKine Therapeutics Novel Diabetes, Atherosclerosis Drugs Receives European Patent Protection
11. Cellectricon Launches Dynaflow® Resolve System Enabling Novel Ion Channel Assays
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Novel nanotherapeutic delivers clot-busting drugs directly to obstructed blood vessels
(Date:11/18/2014)... 18, 2014 Array Architects is proud ... expertise to the nation's hospitals and health systems. It ... those dedicating their careers to the advancement of both ... in her respective field, Laura Silvoy has been chosen ... 2014 Winter Simulation Conference. , Laura will present ...
(Date:11/18/2014)... , Nov. 18, 2014  Asterias Biotherapeutics, Inc. ... the emerging field of regenerative medicine, today announced ... progenitor cells) for complete cervical spinal cord injury ... "Top Advanced Therapies Projects to Watch" by Elsevier ... receive this significant industry honor, which represents independent ...
(Date:11/18/2014)... 2014  Novira Therapeutics, Inc., a privately held biopharmaceutical ... hepatitis B virus (HBV) infection, today announced that ... Scientific Advisory Board (SAB).  "We are ... Christian S. Schade , Chief Executive Officer of Novira.  ... will be invaluable to Novira as our lead core ...
(Date:11/17/2014)... , Nov. 17, 2014 Soligenix, ... late-stage biopharmaceutical company developing products that address unmet ... and biodefense, announced today the formation of a ... guidance to the Company as it advances the ... for the treatment of cutaneous T-cell lymphoma (CTCL), ...
Breaking Biology Technology:Array Healthcare Simulation Expert Slated to Speak at Winter Simulation Conference 2Asterias Biotherapeutics Named as a "Top Advanced Therapies Projects to Watch" and Will Present at the Therapeutic Area Partnerships Conference 2Asterias Biotherapeutics Named as a "Top Advanced Therapies Projects to Watch" and Will Present at the Therapeutic Area Partnerships Conference 3Novira Therapeutics Announces Appointment of Brian F. Daniels, M.D., to its Scientific Advisory Board 2Novira Therapeutics Announces Appointment of Brian F. Daniels, M.D., to its Scientific Advisory Board 3Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 2Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 3Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 4Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 5Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 6
... to Detail Latest Cardiac Surgery Technology to be Held ... January 26th at 6:30 p.m. ... leading,medical technology companies will host the first annual After Hours ... aboard the yacht,"Princess Lady." The invitation-only event, immediately preceding the,largest ...
... Jan. 15 In response to the,Federal Drug ... are safe for human consumption, Smithfield Foods, Inc.,(NYSE: ... company is not planning,to produce meat products from ... relatively new. As thoughtful leaders in our industry,we ...
... BioSpecifics,Technologies Corp. (Pink Sheets: BSTC.PK) today announced ... stock, in a private placement,offering to an investment ... share for,aggregate proceeds to the Company of $2,100,000., ... Corp. is a biopharmaceutical company that has,developed and ...
Cached Biology Technology:Five Medical Technology Companies Host Premier Event for Cardiothoracic Surgeons 2Five Medical Technology Companies Host Premier Event for Cardiothoracic Surgeons 3Five Medical Technology Companies Host Premier Event for Cardiothoracic Surgeons 4
(Date:11/4/2014)... – (Nov. 4, 2014) – A majority of Madagascar,s ... that could have serious consequences for the rainforests they ... shows the positive impacts lemurs can have on rainforest ... their disappearance could have on the region,s rich biodiversity. ... have fruits eaten by lemurs. Lemurs in turn ...
(Date:11/3/2014)... report that low birth weight and preterm birth are ... in adulthood. Findings published in the American College of ... indicate that low birth weight and pre-term babies were ... OA as adults. , According to the ACR, ... diagnosed with clinical OA. Symptoms of OA range from ...
(Date:10/31/2014)... HMS Center for Biomedical Informatics (CBMI) has received two ... infusion of support will enable the center to continue ... and the other involving new approaches to precision medicine. ... National Human Genome Research Institute and the National Institute ... Center for Excellence in Genomic Science, or CEGS. , ...
Breaking Biology News(10 mins):Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3Preterm, low birth-weight babies may need new hips in adulthood 2Transforming 'big data' into knowledge 2Transforming 'big data' into knowledge 3
... the first time, scientists have mapped the genome--the genetic code--of ... to maintain the genetic diversity of captive and wild orangutans. ... used to help improve our understanding of the evolution of ... Science Foundation, the orangutan study appears in the Jan. 27 ...
... What separates humans from Chimpanzees? Is it ... and behavior capabilities? To Professor Wallace Arthur it is ... book Evolution: A Developmental Approach sits between the ... approach to provide a complete view on the evolutionary ...
... release is available in German . , ... jointly develop new battery materials at KIT in the ... was signed by Professor Eberhard Umbach, President of KIT, ... Executive Directors of BASF SE, Ludwigshafen. The BELLA (Batteries ...
Cached Biology News:Scientists determine what makes an orangutan an orangutan 2Scientists determine what makes an orangutan an orangutan 3BASF and Karlsruhe Institute of Technology develop tomorrow's battery materials 2
...
Anti-MMP-7, aminoterminal end active enzyme; rabbit host...
Mouse monoclonal [CLB-SW16 (formerly 708)] to CD42d (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 2814 SwissProtID: P40197...
Mouse monoclonal [7C6] to Bcr-abl ( Abpromise for all tested applications). SwissProtID: P11274...
Biology Products: